UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating

UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating.

MT NewswiresApr 2 23:50

Kyowa Kirin's Rare Disease Therapy Becomes World's Most Expensive Drug

Seeking AlphaMar 21 00:11

13 Best Biotech Stocks To Buy Under $20

Yahoo FinanceMar 13 19:07

AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Sec

BenzingaMar 4 20:56

UniQure Is Maintained at Neutral by Mizuho

UniQure Is Maintained at Neutral by Mizuho

Dow JonesMar 4 20:22

Mizuho Maintains Neutral on UniQure, Lowers Price Target to $7

Mizuho analyst Uy Ear maintains uniQure with a Neutral and lowers the price target from $10 to $7.

Analyst UpgradesMar 4 20:12